An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity

J Int Med Res. 2019 Oct;47(10):4691-4700. doi: 10.1177/0300060519865351. Epub 2019 Aug 23.

Abstract

Objective: Impaired glucose homeostasis in polycystic ovary syndrome (PCOS) is associated with obesity, age, and disease phenotype. This study aimed to investigate the glucagon-like peptide-1 (GLP-1) response in patients with obesity and PCOS with normal glucose tolerance (NGT) or prediabetes.

Methods: Twenty-six women with obesity and PCOS were included. Thirteen women had NGT and 13 had prediabetes. Serum glucose, insulin, and GLP-1 levels were measured during an oral glucose tolerance test. Beta-cell function and insulin resistance were determined.

Results: Women with prediabetes had significantly lower GLP-1 levels than did those with NGT after a glucose load. GLP-1 levels <3.02 pM at 120 minutes were associated with prediabetes. Women with prediabetes had a lower oral glucose insulin sensitivity (OGIS) index and greater amount of visceral adipose tissue than did those with NGT. Plasma GLP-1 levels at 120 minutes were correlated with visceral adiposity and the OGIS index. A change in GLP-1 levels was correlated with a family history of type 2 diabetes.

Conclusion: The GLP-1 response is lower in patients with obesity, PCOS, and prediabetes than in those with obesity, PCOS, and NGT. Further investigation of the GLP-1 response as a potential separate risk factor for prediabetes in PCOS is required.

Keywords: Prediabetes; glucagon-like peptide-1 (GLP-1) response; insulin; normal glucose tolerance; obesity; polycystic ovary syndrome.

MeSH terms

  • Adult
  • Female
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucose Tolerance Test
  • Humans
  • Incretins / metabolism
  • Obesity / complications*
  • Polycystic Ovary Syndrome / complications*
  • Prediabetic State / complications*

Substances

  • Incretins
  • Glucagon-Like Peptide 1